Navigation Links
One-Third of Patients Discontinue Common Breast Cancer Therapy

PRINCETON, N.J.--(BUSINESS WIRE)--Mar 15, 2007 - An alarming study that appeared in the March 1, 2007 issue of CANCER (a peer-reviewed journal of the American Cancer Society), reports that one-third of women taking the standard five-year regimen of the hormonal breast cancer treatment tamoxifen citrate, discontinue therapy early.(1)

According to the authors, non-compliance with tamoxifen tablets is a major issue that may negatively affect treatment efficacy. While tamoxifen tablets remain a standard of care, according to these data, they are associated with compliance and persistency issues. Oncologists need to identify those at risk of non-persistence and develop strategies to combat this barrier to treatment success.

Patients at risk of non-persistence include those who prefer alternative delivery formats to traditional pills/tablets, such as liquid formulations. SOLTAMOX, the only liquid form of tamoxifen citrate, is an alternative for women who require tamoxifen therapy. SOLTAMOX may be an attractive option for women who do not like pills or cannot swallow pills. SOLTAMOX is approved by the FDA and is available in the U.S. through Cytogen Corporation. For more information about SOLTAMOX, please visit www.soltamoxus.com. -0-

WHO:   Linda Vahdat, MD, Weill Cornell Medical Center. Dr. Vahdat is a

        leading breast cancer expert and a participant in the

        Compliance Strategic Initiative -- a program designed to

        increase awareness compliance and to raise awareness

        importance of hormonal therapy in breast cancer.


WHAT:  Dr. Vahdat is available to speak with media regarding the

        importance of tamoxifen compliance and the need to offer

        patients more options.


WHEN:  March 2007


WHERE: Please contact Eliza Schleifstein (973) 387-0342 to set up a

        convenient time to interview Dr. Vahdat.

About SOLTAMOX

SOLTAMOX (tamoxifen c itrate) is now available in U.S. pharmacies nationwide. SOLTAMOX is the only liquid form of the hormonal breast cancer therapy, tamoxifen, approved by the FDA and available in the U.S. SOLTAMOX is indicated for the treatment of metastatic breast cancer, adjuvant treatment of breast cancer, ductal carcinoma in situ (DCIS), and reduction in breast cancer incidence in high risk women.

WARNING - For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer: Serious and life-threatening events associated with tamoxifen in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism.

Incidence rates for these events were estimated from the NSABP P-1 trial (see CLINICAL PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer Incidence In High Risk Women).

Uterine malignancies consist of both endometrial adenocarcinoma (incidence rate per 1,000 women-years of 2.20 for tamoxifen vs. 0.71 for placebo) and uterine sarcoma (incidence rate per 1,000 women years of 0.17 for tamoxifen vs. 0.0 for placebo) *. For stroke, the incidence rate per 1,000 women years was 1.43 for tamoxifen vs. 1.00 for placebo**.

For pulmonary embolism, the incidence rate per 1,000 women years was 0.75 for tamoxifen versus 0.25 for placebo**. Some of the strokes, pulmonary emboli, and uterine malignancies were fatal.

Health care providers should discuss the potential benefits versus the potential risks of these serious events with women at high risk of breast cancer and women with DCIS considering tamoxifen to reduce their risk of developing breast cancer. The benefits of tamoxifen outweigh its risks in women already diagnosed with breast cancer.

Full prescribing information for SOLTAMOX is available on Cytogen's Web site at http://www.cytogen.com.

(1) Barron, Thomas I., Roisin Connolly, Bennett Kathleen, John Feely, and M. John Kennedy. "Early Discon tinuation of Tamoxifen." Cancer 109 (2007): 1-9.

Contact

JFK Communications, Inc.
Eliza Schleifstein, 973-387-0342
efschleifstein@aol.com


'"/>




Related medicine technology :

1. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
2. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
3. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
4. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
5. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
9. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
10. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
11. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology:
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
Breaking Medicine News(10 mins):